Circassia puts money where mouth is; IPO floats at top price
This article was originally published in Scrip
Executive Summary
UK allergy company Circassia Pharmaceuticals has priced its initial public share offering at the top of its price range on the London Stock Exchange, marking the first significant listing in the sector in Europe for quite some time.
You may also be interested in...
Mite Trial Failure 'The Final Straw' As Circassia Ends Anti-Allergy Investing
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.